sellWeak cluster of 210b5-1 plan
James Edward Doyle sold $120k of EXAS
director at EXACT SCIENCES CORP. 2,000 shares at an average of $60.00, traded Oct 9, 2025, filed Oct 10, 2025.
Warning score
13Value
$120k
2,000 shares
Holdings after
57,962
-3% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleDirector
- +10Trade size$120k at market
- 0Share of holdings soldSold 3.3% of holdings
- +8Cluster2 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001193125-25-237233, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 9, 2025 | SOpen-market sale Common Stock10b5-1 | -2,000 | $60.00 | $120k | 57,962 | Oct 10, 2025 |
Related signals
Other insiders at EXACT SCIENCES CORP and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 11Weak | EXACT SCIENCES CORP | James Herriott SVP, General Counsel & Sec | $70k 1,000 shares | -8% | |
| 24Weak | EXACT SCIENCES CORP | Jacob A Orville EVP, GM, Screening | $375k 5,000 shares | -18% | |
| 27Weak | EXACT SCIENCES CORP | Brian Baranick EVP, GM, Precision Oncology | $200k 2,858 shares | -11% | |
| 25Weak | EXACT SCIENCES CORP | James Herriott SVP, General Counsel & Sec | $105k 1,500 shares | -11% | |
| 37Weak | EXACT SCIENCES CORP | Katherine S Zanotti director | $780k 12,000 shares | -16% | |
| 12Weak | EXACT SCIENCES CORP | James Herriott SVP, General Counsel & Sec | $90k 1,500 shares | -10% | |
| 2Weak | EXACT SCIENCES CORP | James Edward Doyle director | $62k 1,485 shares | -2% | |
| 6Weak | EXACT SCIENCES CORP | Katherine S Zanotti director | $171k 3,207 shares | -4% | |
| 50Moderate | EXASbuy EXACT SCIENCES CORP | Kevin T Conroy President and CEO | $1.0M 19,500 shares | +2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.